Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of CLUSTOID Birke for birch pollen allergic rhinitis
2011-002296-42Phase 2Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Oct 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of birch pollen allergoid in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (5 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Efficacy based on titrated nasal provocation test improvement. Started Oct 2019; status: completed.
02
Drugs
birch pollen allergoid
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2011-002296-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002296-42.